Clin Nucl Med. 2018 Nov;43(11):802-810. doi: 10.1097/RLU.0000000000002276. ABSTRACT PURPOSE: The aim of this study was to systematically review the literature to assess the role of Ga PET imaging in neuroendocrine tumors (NETs). MATERIALS AND METHODS: The literature was searched using…
[18F]DCFPyL PET-MRI/CT for unveiling a molecularly defined oligorecurrent prostate cancer state amenable for curative-intent ablative therapy: study protocol for a phase II trial
BMJ Open. 2020 Apr 22;10(4):e035959. doi: 10.1136/bmjopen-2019-035959. ABSTRACT INTRODUCTION: The oligometastatic (OM) disease hypothesis of an intermediate metastatic state with limited distant disease deposits amenable for curative therapies remains debatable. Over a third of prostate cancer (PCa) patients treated with…
18F-DCFPyL PET/CT in Patients with Subclinical Recurrence of Prostate Cancer: Effect of Lesion Size, Smoothing Filter, and Partial-Volume Correction on PROMISE Criteria
J Nucl Med. 2020 Nov;61(11):1615-1620. doi: 10.2967/jnumed.120.241737. Epub 2020 Mar 20. ABSTRACT Our purpose was to determine the effect of a smoothing filter and partial-volume correction (PVC) on measured prostate-specific membrane antigen (PSMA) activity in small metastatic lesions and to…
A Prospective Study of 18F-DCFPyL PSMA PET/CT Restaging in Recurrent Prostate Cancer following Primary External Beam Radiotherapy or Brachytherapy
Int J Radiat Oncol Biol Phys. 2020 Mar 1;106(3):546-555. doi: 10.1016/j.ijrobp.2019.11.001. Epub 2019 Nov 12. ABSTRACT PURPOSE: Radio-recurrent prostate cancer is typically detected by a rising prostate-specific antigen and may reflect local or distant disease. Positron emission tomography (PET) radiotracers…
68Ga PET Imaging in Patients With Neuroendocrine Tumors: A Systematic Review and Meta-analysis
Clin Nucl Med. 2018 Nov;43(11):802-810. doi: 10.1097/RLU.0000000000002276. ABSTRACT PURPOSE: The aim of this study was to systematically review the literature to assess the role of Ga PET imaging in neuroendocrine tumors (NETs). MATERIALS AND METHODS: The literature was searched using…
Neuroendocrine Tumors: Imaging Perspective
PET Clin. 2021 Jul;16(3):353-364. doi: 10.1016/j.cpet.2021.03.002. ABSTRACT This article summarizes the role of PET imaging for detection, characterization, and theranostic/therapy planning for neuroendocrine tumors. Topics in this article span overall imaging accuracy with mostly 68Ga-DOTA-peptide imaging as well as basic…
Detection of clinically significant prostate cancer with 18F-DCFPyL PET/multiparametric MR
Eur J Nucl Med Mol Imaging. 2021 Oct;48(11):3702-3711. doi: 10.1007/s00259-021-05355-7. Epub 2021 Apr 12. ABSTRACT PURPOSE: To assess whether 18F-DCFPyL PET/multiparametric (mp)MR contributes to the diagnosis of clinically significant (cs) prostate cancer (PCa) compared to mpMR in patients with suspicion…
Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis
Eur Urol. 2021 Sep;80(3):374-382. doi: 10.1016/j.eururo.2021.02.031. Epub 2021 Mar 6. ABSTRACT BACKGROUND: The hypothesis of a curable oligometastatic prostate cancer (PCa) state remains to be clinically-proven. Conventional imaging often fails to localize early recurrences, hampering the potential for radical approaches.…
Quantitative 68Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with 177Lu-DOTATATE
J Nucl Med. 2021 Oct;62(10):1406-1414. doi: 10.2967/jnumed.120.256727. Epub 2021 Feb 12. ABSTRACT The aim of this study was to determine whether quantitative PET parameters on baseline 68Ga-DOTATATE PET/CT and interim PET (iPET) performed before the second cycle of therapy are…
Utilization of Salvage and Systemic Therapies for Recurrent Prostate Cancer as a Result of 18F-DCFPyL PET/CT Restaging
Adv Radiat Oncol. 2020 Sep 9;6(1):100553. doi: 10.1016/j.adro.2020.08.010. eCollection 2021 Jan-Feb. ABSTRACT PURPOSE: Our purpose was to investigate the effect of the addition of prostate-specific membrane antigen (PSMA)-targeted positron emission tomography/computed tomography (PET/CT) in patients with recurrent prostate cancer post-primary…